Keros Therapeutics (NASDAQ:KROS) Given New $23.00 Price Target at Oppenheimer

Keros Therapeutics (NASDAQ:KROS) had its target price reduced by Oppenheimer from $63.00 to $23.00 in a research report report published on Thursday morning,Benzinga reports. They currently have an outperform rating on the stock.

A number of other research analysts have also recently issued reports on KROS. TD Cowen cut shares of Keros Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. William Blair lowered shares of Keros Therapeutics from an “outperform” rating to a “market perform” rating in a report on Thursday, December 12th. Jefferies Financial Group started coverage on Keros Therapeutics in a research note on Tuesday, November 5th. They set a “buy” rating on the stock. Wedbush reissued an “outperform” rating and issued a $84.00 target price on shares of Keros Therapeutics in a research note on Thursday, November 7th. Finally, Wells Fargo & Company raised their price target on Keros Therapeutics from $88.00 to $111.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 11th. Five research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, Keros Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $52.56.

Keros Therapeutics Stock Up 3.2 %

KROS stock opened at $10.86 on Thursday. Keros Therapeutics has a twelve month low of $9.77 and a twelve month high of $73.00. The company has a market cap of $439.94 million, a P/E ratio of -2.08 and a beta of 1.43. The business’s fifty day moving average is $36.37 and its 200-day moving average is $47.13.

Keros Therapeutics (NASDAQ:KROS) last released its earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share for the quarter, missing the consensus estimate of ($1.28) by ($0.13). The company had revenue of $0.39 million during the quarter. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The company’s revenue for the quarter was up 4750.0% on a year-over-year basis. During the same quarter last year, the firm earned ($1.33) earnings per share. Research analysts anticipate that Keros Therapeutics will post -4.74 earnings per share for the current fiscal year.

Institutional Trading of Keros Therapeutics

A number of institutional investors have recently made changes to their positions in KROS. FMR LLC increased its stake in Keros Therapeutics by 3.8% in the 3rd quarter. FMR LLC now owns 4,899,134 shares of the company’s stock valued at $284,493,000 after buying an additional 179,374 shares during the last quarter. Alkeon Capital Management LLC grew its holdings in shares of Keros Therapeutics by 18.7% in the 3rd quarter. Alkeon Capital Management LLC now owns 1,897,601 shares of the company’s stock valued at $110,194,000 after acquiring an additional 298,694 shares in the last quarter. Darwin Global Management Ltd. increased its position in shares of Keros Therapeutics by 6.3% in the second quarter. Darwin Global Management Ltd. now owns 1,525,902 shares of the company’s stock valued at $68,772,000 after acquiring an additional 89,952 shares during the last quarter. Point72 Asset Management L.P. raised its holdings in Keros Therapeutics by 155.9% during the third quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company’s stock worth $55,025,000 after acquiring an additional 577,220 shares in the last quarter. Finally, Holocene Advisors LP boosted its position in Keros Therapeutics by 22.5% during the third quarter. Holocene Advisors LP now owns 843,110 shares of the company’s stock valued at $48,959,000 after purchasing an additional 154,784 shares during the last quarter. Institutional investors own 71.56% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.